Abstract: Serial administration of two complementary compositions effectively reduces and stabilizes glucose levels in the blood of mammals, specifically in pre-diabetic patients and patients with type 2 diabetes mellitus (T2DM). The first composition (Comp1) comprises (?)-hydroxycitric acid ((?)-HCA), magnesium salt (Mg) and konjac mannan (KM). The second composition (Comp2) comprises chromium picolinate (CrPic), magnesium salt (Mg) and alpha-lipoic acid (?-LA). The second composition may include one or more of Comp1, cinnamon extract (CE) and American ginseng (AG).

Abstract: The invention discloses compositions that effectively reduce and stabilize glucose levels in the blood of mammals, specifically in pre-diabetic patients and patients with type 2 diabetes mellitus (T2DM). Composition 1 (Comp1) reinforces efficacy of Mg salt to reduce glucose level by the combination of Mg salt with anti-inflammatory agents konjac-glucomannan (KGM), vitamin C and alpha-lipoic acid (?-LA). Composition 2 (Comp2) provides safety for chromium picolinate (CrPic) by the combination of CrPic with anti-inflammatory agents KGM, vitamin C and ?-LA that inhibits oxygen radicals. Compositions may optionally include cinnamon extract (CE) or another insulinogenic nutraceutical agent, American ginseng (AG), Uncaria tomentosa, Uncaria guianensis and Urtica dioica.

Abstract: The invention discloses aromatic amides and sulfonates to treat or prevent type 2 diabetes mellitus (T2DM), the pathological consequences of T2DM, to inhibit amyloidosis or to prevent death of ?-cells of the pancreas.

Abstract: The invention discloses compositions that effectively reduce and stabilize glucose levels in the blood of mammals, specifically in pre-diabetic patients and patients with type 2 diabetes mellitus (T2DM). Composition 1 (Comp1) reinforces efficacy of Mg salt to reduce glucose level by the combination of Mg salt with anti-inflammatory agents konjac-glucomannan (KGM), vitamin C and alpha-lipoic acid (?-LA). Composition 2 (Comp2) provides safety for chromium picolinate (CrPic) by the combination of CrPic with anti-inflammatory agents KGM, vitamin C and ?-LA that inhibits oxygen radicals. Compositions may optionally include cinnamon extract (CE) or another insulinogenic nutraceutical agent, American ginseng (AG), Uncaria tomentosa, Uncaria guianensis and Urtica dioica.

Abstract: The invention discloses serial administration of two complementary compositions that effectively reduce and stabilize glucose levels in the blood of mammals, specifically in pre-diabetic patients and patients with type 2 diabetes mellitus (T2DM). The first composition (Comp1) comprises (?)-hydroxycitric acid ((?)-HCA), magnesium salt (Mg) and konjac mannan (KM). The second composition (Comp2) comprises chromium picolinate (CrPic), magnesium salt (Mg) and alpha-lipoic acid (?-LA). The second composition optionally may include one or more of Comp1, cinnamon extract (CE) and American ginseng (AG).

Abstract: The invention discloses aromatic amides and sulfonates to treat or prevent type 2 diabetes mellitus (T2DM), the pathological consequences of T2DM, to inhibit amyloidosis or to prevent death of ?-cells of the pancreas.